Patents Issued in October 8, 2020
  • Publication number: 20200316130
    Abstract: This document provides materials and methods for enhancing bone cell differentiation. For example, compositions containing an epigenetic drug, an actin modulator, and/or one or more osteogenic differentiation factors that can be used to enhance bone cell differentiation are provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: October 8, 2020
    Inventors: Andre J. van Wijnen, Amel Dudakovic
  • Publication number: 20200316131
    Abstract: The present invention relates to a method of treating a subject having drug-resistant cancer, comprising administering a composition comprising exosomes derived from differentiating stem cells as an active ingredient. The exosomes isolated differentiating stem cells according to the present invention have an excellent expression rate of bioactive factors affecting differentiation and have an effect of facilitating reprogramming of cancer stem cells and differentiating them into cancer cells with weakened drug resistance.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 8, 2020
    Inventors: Yong Woo CHO, Kyoung-Soo LEE, Ji Suk CHOI, Woolee CHO
  • Publication number: 20200316132
    Abstract: The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorders.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 8, 2020
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Guoping Feng, Boaz Barak, Zhigang He
  • Publication number: 20200316133
    Abstract: The present invention refers to micro-fragmented fat or a composition comprising micro-fragmented fat for use in the treatment of a systemic disease, preferably associated to or caused by sepsis. Moreover, the micro-fragmented fat or the composition comprising micro-fragmented fat is used for treating a systemic, inflammatory, immune, or chronic disease, said disease being intended as a consequence of septic disease. Preferably, the micro-fragmented fat is useful for treating both the acute (early) and late stages of sepsis.
    Type: Application
    Filed: May 12, 2017
    Publication date: October 8, 2020
    Inventors: Carlo Ferdinando Maria TREMOLADA, Pierre ROCHETEAU
  • Publication number: 20200316134
    Abstract: Methods of implanting therapeutic cells in a subject and methods of preparing pancreatic islet cells for implantation into a subject, prior to implantation into a subject, are provided herein.
    Type: Application
    Filed: March 26, 2018
    Publication date: October 8, 2020
    Inventors: Camillo Ricordi, Dora M. Berman-Weinberg, Marta Garcia Contreras, Diego Correa, Alice Tomei
  • Publication number: 20200316135
    Abstract: Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy.
    Type: Application
    Filed: November 8, 2019
    Publication date: October 8, 2020
    Applicant: ViaCyte, Inc.
    Inventors: Laura Martinson, Evert Kroon, Kevin D'Amour, Emmanuel Edward Baetge
  • Publication number: 20200316136
    Abstract: Disclosed is a liquid medicament/supplement composition including a non-winterized marine source oil (e.g., oil derived from fish, krill, and/or squid), a food grade or pharmaceutically acceptable form of vitamin D3 or a derivative thereof admixed in the non-winterized marine source oil, a food grade or pharmaceutically acceptable form of vitamin A or a derivative thereof admixed in the non-winterized marine source oil, optionally a food grade or pharmaceutically acceptable form of CoQ10 or a derivative thereof admixed in the non-winterized marine source oil, a food grade or pharmaceutically acceptable form of concentrated eicosapentaenoic acid and docosahexaenoic acid or ethyl ester, glyceride ester or salt of the acid and polyphenol rich vegetable oil admixed in the non-winterized marine source oil, and optionally a food grade or pharmaceutically acceptable form of melatonin or a derivative thereof admixed in the non-winterized marine source oil.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 8, 2020
    Inventors: Bo Reidar Martinsen, Leif Andreas Riege
  • Publication number: 20200316137
    Abstract: A method for processing traditional Chinese medicine using a calcium-based ion solution and an application thereof. A solution formed by a calcium-based ion solution and Chinese spirits is used to soak a traditional Chinese medicine prescription; the calcium-based ion solution refers to a solution containing calcium ions with a mass percentage of 0.3-10%; and the Chinese spirits is a spirit containing more than 35% alcohol by volume. Also provided is an application of a soaking liquid for processing traditional Chinese medicine in preparing, from a traditional Chinese medicine prescription, a meridians and collaterals administration agent applied on skin, a preparation extracted from traditional Chinese medicine soaked using a soaking solution formed by “a calcium-based ion solution and a spirit” has a better effect of guiding skin penetration.
    Type: Application
    Filed: August 4, 2017
    Publication date: October 8, 2020
    Inventor: Jianguo ZHAO
  • Publication number: 20200316138
    Abstract: The present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III, for use in the treatment and/or prevention of visceral abdominal pain in an individual. The present invention also concerns compositions comprising said bacterial strains as well as specific strains as such.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Philippe LANGELLA, Sylvie MIQUEL, Rebeca MARTIN ROSIQUE, Luis BERMUDEZ HUMARAN, Muriel THOMAS, Harry SOKOL, Frédéric CARVALHO, Vassilia THEODOROU
  • Publication number: 20200316139
    Abstract: The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.
    Type: Application
    Filed: April 2, 2019
    Publication date: October 8, 2020
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Furqan Ali, Sivakumar Arumugam, Shaheen Majeed
  • Publication number: 20200316140
    Abstract: The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 8, 2020
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Kirankumar Beede, Sivakumar Arumugam, Shaheen Majeed
  • Publication number: 20200316141
    Abstract: Described herein is a composition containing probiotic bacteria and a fermentate that can increase IPA production. The composition comprises one or more bacteria having a nucleic acid sequence with at least 80% homology to the nucleic acid sequence of SEQ ID NO: 1, a fermentate comprising soy flour, a yeast, and a proteolytic enzyme, and an excipient, carrier, and/or diluent. The composition can promote brain health and/or nervous system function.
    Type: Application
    Filed: April 2, 2020
    Publication date: October 8, 2020
    Inventors: Arvind Venkataraman, Chelsay Lynn Brewster, Kimberly Conner Kozak, Lijuan Li
  • Publication number: 20200316142
    Abstract: A method for growing probiotic organisms wherein the growth media includes prebiotics especially selected and prepared to be paired with the probiotic organisms being grown. The prebiotic formula is optimized to grow the desired probiotic organisms, as well as important byproducts of the growth process. Specialized freeze-drying buffers may also be paired with certain probiotic organisms for the freeze-drying process. Specific products may utilize selected probiotic organisms grown and supported with paired prebiotic formulas to promote and maintain physiological health in a subject.
    Type: Application
    Filed: May 28, 2020
    Publication date: October 8, 2020
    Inventors: Shayne Morris, Michael Benson
  • Publication number: 20200316143
    Abstract: The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 8, 2020
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey, Shaheem Majeed
  • Publication number: 20200316144
    Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
    Type: Application
    Filed: February 24, 2020
    Publication date: October 8, 2020
    Inventors: Remy Burcelin, DIDIER CARCANO, SAMPO LAHTINEN
  • Publication number: 20200316145
    Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children.
    Type: Application
    Filed: February 3, 2020
    Publication date: October 8, 2020
    Inventors: Gregory Leyer, Arthur Ouwehand
  • Publication number: 20200316146
    Abstract: A method of modifying a virus for in vivo delivery to a region of interest includes forming an enveloping composition including a lipid conjugate formed by conjugating at least one lipid with at least one hydrophilic compound via a linkage which is cleavable under conditions present in the region of interest and combining the virus with the enveloping composition to encompass the virus within the enveloping structure.
    Type: Application
    Filed: March 24, 2017
    Publication date: October 8, 2020
    Inventors: SONG LI, STEPHEN HOWARD THORNE
  • Publication number: 20200316147
    Abstract: Certain embodiments are directed to composition for inducing an immune response against xCT that is directed to cancer stem cells expressing xCT.
    Type: Application
    Filed: March 16, 2020
    Publication date: October 8, 2020
    Inventors: Federica CAVALLO, Stefania LANZARDO, Laura CONTI, John P. O'ROURKE, Federica PERICLE
  • Publication number: 20200316148
    Abstract: The custard apple peel nanoparticles may be manufactured by extracting custard apple peels in a solvent, spraying the custard apple peel extracts into boiling water under ultrasonic conditions to produce a first mixture, sonicating the mixture, stirring the mixture, and drying the mixture to obtain custard apple peel nanoparticles. In an embodiment, the custard apple peel may be peel of Annona reticulata. In an embodiment, the custard apple peel nanoparticles may have improved antibacterial or antioxidant properties.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 8, 2020
    Inventors: HANY M. YEHIA, HATEM SALAMA ALI, EBTESAM MOHAMMED AL OLAYAN, MANAL FAWZY ELKHADRAGY, MOHAMED FEKRY MANSOUR SERAG ELDIN, MANAL AHMED AWAD
  • Publication number: 20200316149
    Abstract: The custard apple peel nanoparticles may be manufactured by extracting custard apple peels in a solvent, spraying the custard apple peel extracts into boiling water under ultrasonic conditions to produce a first mixture, sonicating the mixture, stirring the mixture, and drying the mixture to obtain custard apple peel nanoparticles. In an embodiment, the custard apple peel may be peel of Annona reticulata. In an embodiment, the custard apple peel nanoparticles may have improved antibacterial or antioxidant properties.
    Type: Application
    Filed: November 26, 2019
    Publication date: October 8, 2020
    Inventors: Hany M. YEHIA, Hatem Salama ALI, Ebtesam Mohammed AL OLAYAN, Manal Fawzy ELKHADRAGY, Mohamed Fekry Mansour SERAG ELDIN, Manal Ahmed AWAD
  • Publication number: 20200316150
    Abstract: The present invention is related to a novel gastroretentive swellable oral dosage form for sustained or delayed release of bergenin, a active constituent of Bergenia ciliata extract/fraction and a process for preparing the same wherein the extract is wet-granulated using excipients i.e. biodegradable polymers and/or non-biodegradable polymers alone or in combination, and the said granules are either filled into a capsule or compressed into a tablet. The said formulation comprising a granulated extract of bergenin-rich Bergenia ciliata with polymers has resulted in a sustained release of extract in the stomach over a period of 16-24 hrs. The said formulations are useful for the treatment of inflammatory diseases.
    Type: Application
    Filed: September 11, 2018
    Publication date: October 8, 2020
    Inventors: Sonali Sandip Bharate, Rohit Singh, Mehak Gupta, Bikarma Singh, Anil Kumar Katare, Ajay Kumar, Sandip Bibishan Bharate, Ram Vishwakarma
  • Publication number: 20200316151
    Abstract: The present disclosure relates to a dissolvable thin oral tape, film or strip or segment thereof composition or device, including a film former, at least one cannabinoid, menthol, caffeine and vitamins, where the menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.
    Type: Application
    Filed: March 3, 2020
    Publication date: October 8, 2020
    Inventors: Babak Ghalili, Emma Ghalili
  • Publication number: 20200316152
    Abstract: Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventor: Lisa GENG
  • Publication number: 20200316153
    Abstract: An externally-used traditional Chinese medicine preparation for treating rhinitis, and a preparation method therefor. The externally-used traditional Chinese medicine preparation is prepared by using the following components in parts by weight: 1 to 6 parts of herba asari, 8 to 12 parts of magnolia flowers, 6 to 20 parts of cocklebur fruits, 3 to 8 parts of small centipeda herb, 1 to 6 parts of cutch, 15 to 20 parts of roots of podophyllum hexandrum and 7 to 15 parts of borneol.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 8, 2020
    Inventor: Zhehao Liu
  • Publication number: 20200316154
    Abstract: A cannabinoid composition comprising, purified water, hemp extract having a between 30-70% cannabidiol concentration. The hemp extract being a whole plant extract derived hemp. The composition includes 200-800 mg of ajo sacha paste dissolved in the water in a final concentration of 600 mg paste per 60 ml (2 oz) finished product. The composition further includes sangre de grado is added in the standardized aqueous commercial form at a concentration of 0.5 ml per 60 ml of finished product. The composition includes an excipient chosen from the group consisting of emulsifiers, preservatives, fragrance, flavorings, a carrier oil, and combinations thereof. A method of the invention includes adding these components together to form the composition. In particular, the method includes dissolving equal amounts of 30× Ajo Sacha paste in equal weight hot purified water. Providing a botanical carrier oil and mixing hep CBD oil, commercial Sangre de Grado solution, and Ajo Sacha solution to the botanical carrier oil.
    Type: Application
    Filed: March 19, 2020
    Publication date: October 8, 2020
    Inventor: Manu Sai Malasquez
  • Publication number: 20200316155
    Abstract: The present invention is directed to therapeutic methods for treating benign prostatic hyperplasia (BPH) in a subject comprising administering an effective amount of a herbal mixture, and an anti-BPH agent to said subject where said herbal mixture comprises Astragalus membranaceus and Glycine max; and compositions thereof.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 8, 2020
    Inventor: Sheng-Yung Liu
  • Publication number: 20200316156
    Abstract: A nasal balm including, by weight, 10-50% of shea butter; 10-50% of coconut oil; 10-50% of Cera alba; 1-5% of grapefruit peel oil; 1-10% of Sclerocarya birrea seed oil; 1-10% of Moringa pterygosperma seed oil; and 1-10% of Simmondsia chinensis seed oil.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 8, 2020
    Inventor: Jing RUAN
  • Publication number: 20200316157
    Abstract: The present invention relates to a method of processing plant material to provide products such as food products, dietary supplements, pharmaceuticals, cosmetics and fertilizers. In particular, the invention relates to the processing of fruit and vegetable material to provide a product that can be used as a food source, dietary supplement or a pharmaceutical. Even more particularly, the invention relates to processing of green bananas such that the flesh and skin can be processed through separate streams.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 8, 2020
    Inventor: Robert Ogilvie Watkins
  • Publication number: 20200316158
    Abstract: The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.
    Type: Application
    Filed: May 15, 2020
    Publication date: October 8, 2020
    Inventors: Igor Quinones-Garcia, Lin Guey, Kris Lowe, Vinh Nguyen, Bing He, Amey Bandekar, Sujit Basu
  • Publication number: 20200316159
    Abstract: Disclosed herein are methods and compositions for sustained release of kappa-opioid agonists. The modified kappa-opioid agonists disclosed herein exhibit high peripheral to CNS selectivity, and benefits patients with visceral and neuropathic pain. In some embodiments, these kappa-opioid agonists of formula I are highly specific for kappa receptors with little or no agonist or antagonist activity to mu or delta receptors. In some embodiments, the kappa-opioid agonists of formula I do not cause CNS-dependent adverse effects. The kappa-opioid agonists of formula I may not cross blood-brain barrier to elicit side effects.
    Type: Application
    Filed: June 5, 2017
    Publication date: October 8, 2020
    Inventor: Gautam GHATNEKAR
  • Publication number: 20200316160
    Abstract: The disclosure provides methods of reducing MMP-9 expression and/or MMP-9 activity in a mammalian subject. The disclosure also provides methods of increasing TIMP-1 expression and/or TIMP-1 activity in a mammalian subject. The methods comprise administering a therapeutically effective amount of an aromatic-cationic peptide to a subject in need thereof.
    Type: Application
    Filed: December 2, 2019
    Publication date: October 8, 2020
    Applicant: Stealth Bio Therapeutics Corp
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20200316161
    Abstract: Provided is an agent for preventing and/or treating osteogenesis imperfecta, osteoporosis and/or osteoarthritis, the agent comprising a peptide consisting of one of the following amino acid sequences: (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (SEQ ID NO: 1) and (b) Val-Asn-Pro-Glu (SEQ ID NO: 2). The agent of the present invention can be orally ingested, has osteogenic function, and has a preventive and/or healing-promoting effect on bone fractures and is therefore very useful for prevention and/or treatment of osteogenesis imperfecta, osteoporosis and/or osteoarthritis.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 8, 2020
    Inventors: Chihiro Suzuki, Utano Nakamura, Mujo Kim
  • Publication number: 20200316162
    Abstract: Disclosed are oxytocin compositions having a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist for the treatment of neonatal abstinence syndrome (“NAS”) in a subject. Also disclosed are methods for the treatment of NAS by administering a therapeutically effective amount of oxytocin, an analog or derivative of oxytocin, or an oxytocin receptor agonist to a subject.
    Type: Application
    Filed: April 8, 2019
    Publication date: October 8, 2020
    Inventors: Dean S. Carson, Marc Pentopoulos
  • Publication number: 20200316163
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: December 14, 2018
    Publication date: October 8, 2020
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Publication number: 20200316164
    Abstract: This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.
    Type: Application
    Filed: April 20, 2020
    Publication date: October 8, 2020
    Inventors: Kunwar SHAILUBHAI, Gary S. JACOB, Patrick GRIFFIN
  • Publication number: 20200316165
    Abstract: The present invention provides a method for treating an ocular disease such as age-related macular degeneration (AMD), diabetic retinopathy (DR) or macular edema (ME), which comprises administering to a subject in need thereof a composition comprising a therapeutically effective amount of beauvericin.
    Type: Application
    Filed: April 1, 2020
    Publication date: October 8, 2020
    Applicant: ZIH YUAN TANG Biotechnology Co., Ltd.
    Inventors: Shoei-Sheng LEE, Ming-Jai SU, Lung-Jr LIN, Chao-Min HSU
  • Publication number: 20200316166
    Abstract: This disclosure relates to medicaments and methods for treating and preventing hepatitis B virus-related liver diseases using sufficient dosage. Specifically, the disclosure provides a method for treating and preventing hepatitis B virus-related liver diseases comprising administering to a subject in need of treatment and prevention a sufficient dosage of a polypeptide or a pharmaceutical composition comprising the polypeptide per day, wherein the polypeptide comprises an amino acid sequence derived from hepatitis B virus (HBV) Pre-S1; the sufficient dosage is a daily dosage at which the polypeptide reaches the saturating level in a liver target organ after the polypeptide is administered in the sufficient dose for several days.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 8, 2020
    Inventor: Hongli LIU
  • Publication number: 20200316167
    Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 8, 2020
    Inventors: Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
  • Publication number: 20200316168
    Abstract: The present invention relates to an inhibitor of IGFBP3 binding to TMEM219 and uses thereof for the treatment and/or prevention of an intestinal disease in a subject, in particular the treatment and/or prevention of diabetic enteropathy or inflammatory bowel disease.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 8, 2020
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Publication number: 20200316169
    Abstract: A technology regarding the production, formulation and use of conditioned media and the factors included therein is disclosed. The conditioned media may be inoculated with animal cells, plant cells and any combination thereof. The inoculations may occur simultaneous or at different times. Cells retrieved from different areas of the animal and/or the plant may also be cultured together to form conditioned media and associated growth factors.
    Type: Application
    Filed: April 2, 2020
    Publication date: October 8, 2020
    Inventors: Nathan Newman, Alex Rajangam, Dodanim Talavera-Adame, Harpreet Sidhu
  • Publication number: 20200316170
    Abstract: The present invention relates to novel liquid or semi-liquid nutritional compositions, and powders to generate such liquid or semi-liquid nutritional compositions, that are beneficial in the treatment of malnutrition and malnutrition-related disorders such as weight loss and muscle wasting. When administered regularly, the nutritional compositions according to the present invention contribute to the reversal of malnutrition and malnutrition-related disorders such as weight loss and/or muscle atrophy.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Gerben Carolus Martinus Zondag, Reinder Strijker
  • Publication number: 20200316171
    Abstract: Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 8, 2020
    Inventor: Manoj Kumar Pandey
  • Publication number: 20200316172
    Abstract: The present invention relates to methods for maturing the mucosal defense and rebalancing the immune system preventing a cytokine storm; treatment or prevention of neonatal sepsis, necrotizing enterocolitis, acute and prolonged diarrhea, short bowel syndrome, respiratory illness, respiratory infection, respiratory failure, impaired neurodevelopment and extra uterine growth restriction, the method comprising oral and/or intrapulmonary and/or subcutaneous administration of at least one antimicrobial peptide selected from the group consisting of ?-defensins, ?-defensins, cathelicidins, lactoferrins/lactoferricins and lysozymes and/or GLP-2 or GLP-2 analogs in a preterm infant or a mother about to give birth to a preterm infant.
    Type: Application
    Filed: November 9, 2018
    Publication date: October 8, 2020
    Inventor: Peter Norkild
  • Publication number: 20200316173
    Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.
    Type: Application
    Filed: December 12, 2019
    Publication date: October 8, 2020
    Applicant: Rappaport Family Institute for Research in the Medical Sciences
    Inventor: Yuval Shaked
  • Publication number: 20200316174
    Abstract: Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite.
    Type: Application
    Filed: March 31, 2020
    Publication date: October 8, 2020
    Applicant: Purdue Research Foundation
    Inventors: Philip S. Low, Stewart A. Low, Jeffery Jay Howard Nielsen
  • Publication number: 20200316175
    Abstract: A method of treating or preventing impaired mobility in an older adult includes administering to the older adult an effective amount of a composition containing at least one ingredient for cognitive ability, at least one ingredient for muscle and/or bone quality, and at least one ingredient for joint quality and/or functionality. The older adult can be an elderly individual and/or can have a condition that is one or more of frailty, pre-frailty, sarcopenia, recovering from sarcopenia, malnutrition, at risk of malnutrition, undergoing rehabilitation, and being scheduled to undergo rehabilitation, disorders impacting mobility such as osteoporosis, osteoarthritis, pre-osteoarthritis, osteopenia, cognitive decline. In a non-limiting example of the composition, the at least one ingredient for muscle and/or bone quality and the at least one ingredient for joint quality include a protein source, omega-3 fatty acids, and a polyphenol.
    Type: Application
    Filed: May 24, 2017
    Publication date: October 8, 2020
    Inventors: Marie Noelle Horcajada, Denis Breuille, Claire Boutry, Zamzam Kabiry (Fariba) Roughead
  • Publication number: 20200316176
    Abstract: Undue scarring of healing wounds is decreased and/or the relapse rate of wounds is lowered by applying a composition that includes hemoglobin to the wound area. At least 40% of the hemoglobin in the composition is provided in CO-charged form.
    Type: Application
    Filed: June 23, 2020
    Publication date: October 8, 2020
    Applicant: MÖLNLYCKE HEALTH CARE AB
    Inventor: Michael Sander
  • Publication number: 20200316177
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, which contains, as an active ingredient, a Bacillus amyloliquefaciens GF423 strain, a superoxide dismutase high-producing Bacillus amyloliquefaciens GF424 mutant strain, a superoxide dismutase (SOD) derived from one of these strains, or both the strain and the SOD. The superoxide dismutase derived from the Bacillus amyloliquefaciens GF423 strain (KCTC 13222BP), which is the active ingredient of the present invention, effectively suppresses or degrades reactive oxygen species, and thus has the effect of fundamentally preventing the causes of inflammatory bowel disease caused by reactive oxygen species. Therefore, the composition of the present invention may be developed into various products, including excellent drugs and health functional foods for preventing or treating inflammatory bowel disease.
    Type: Application
    Filed: December 26, 2018
    Publication date: October 8, 2020
    Inventors: Do Young YUM, Jeong Hyun KIM, Jae Gu PAN, Eui Joong KIM, Ji Eun KANG
  • Publication number: 20200316178
    Abstract: The invention provides a composition of glucocerebrosidase, such as velaglucerase alfa, and isofagomine, in a molar ratio of at least about 1:2.5. Also provided is a use of the composition for treatment of a disorder related to a dysfunction in a GCase pathway. The disorder could be a lysosomal storage disease, such as Gaucher disease, Fabry disease, Pompe disease, a mucopolysaccharidoses, or multiple system atrophy. The disorder could also be a neurodegenerative disorder, such as Parkinson disease, Alzheimer's disease, or Lewy body dementia. The composition can have 0.5 to 5.0 mg/kg of glucocerebrosidase and isofagomine in at least about a 3-fold molar excess to the glucocerebrosidase. The composition can be administered intravenously or subcutaneously.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 8, 2020
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Yung Hee PARK, Nancy CHEN, Jun HU, Muthuraman MEIYAPPAN, Thomas Allen MILLER
  • Publication number: 20200316179
    Abstract: Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Jan P. Kraus, Tomas Majtan, Erez Bublil